Demographic, clinical, and laboratory characteristics of rheumatoid arthritis patients. Unless otherwise stated, the number of patients analyzed was 404.
| Characteristics | |
|---|---|
| Female sex | 367 (90.8%) |
| Age, yrs, median ± SD | 53.18 ± 11.59; range 18–89 |
| Ethnicity, n = 393, n (%) | |
| European-derived | 174 (44.3) |
| Mulatto | 167 (42.5) |
| African-derived | 48 (12.2) |
| Asian-derived | 4 (1.0) |
| Disease duration, yrs, median ± SD | 11.16 ± 7.78; range 2–48 |
| Functional class, n = 377, n (%) | |
| Functional class I, | 164 (43.5) |
| Functional class II | 138 (36.6) |
| Functional class III | 60 (15.9) |
| Functional class IV | 15 (4.0 ) |
| Health Assessment Questionnaire score, n = 396, median ± SD | 0.65 ± 0.59; range 0–2.38 |
| Presence of extraarticular manifestations, n = 363 | 115 (31.7%) |
| Drugs | |
| Methotrexate | 295 (73.0%) |
| Prednisone | 244 (60.4%) |
| Antimalarials | 128 (31.7%) |
| Leflunomide | 119 (29.5%) |
| Sulfasalazine | 38 (9.4%) |
| Immunobiologicals | 21 (5.2%) |
| RF-positive ≥ 20 IU/ml, n = 390 | 248 (61.4%) |
| ACPA-positive > 20 U/ml, n = 390 | 307 (76.0%) |
| Height, meters, median ± SD | 1.58 ± 0.07; range 1.34–1.83 |
| Body mass index, n = 272, mean ± SD | 26.70 ± 4.60; range 16.65–41.66 |
| Total Sharp score, mean ± SD | 109.7 ± 74.8; range 0–379 |
RF: rheumatoid factor; ACPA: anticitrullinated peptide antibody.